PPD Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

PPD today announced that its parent company, PPD, Inc. (formerly known as Eagle Holding Company I), has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of the parent company’s common stock.

12 Nov. 2019

PPD’s SiteCoach Training to Enable More Health Care Providers to Conduct Clinical Trials

PPD has launched PPD’s SiteCoach, providing advanced clinical research training, coaching and support to physicians, hospitals and academic institutions that are new to clinical research.

30 Oct. 2019

PPD Repeats as Best CRO at World ADC Awards for Advancing Cancer Research

PPD has been named Best CRO Provider for the second time in the last three years at the World ADC Awards.

17 Oct. 2019

PPD Named a CSO50 Award Winner for Excellence in Information Security Risk Management

PPD has been named a CSO50 Award winner for information security initiatives demonstrating outstanding business value and thought leadership.

03 Oct. 2019

PPD Expanding Bioanalytical Laboratory Capabilities

PPD is expanding its bioanalytical laboratory in Richmond, Virginia, enhancing its ability to provide industry-leading capabilities to meet biopharmaceutical clients’ increasing research needs.

19 Sept. 2019

PPD’s Accelerated Enrollment Solutions Acquires Global Site Business from Bioclinica

Accelerated Enrollment Solutions has acquired the clinical research site business of Bioclinica, expanding its global footprint and solidifying AES’ leadership position in patient access and site conduct.

05 Sept. 2019

Harbour BioMed and PPD Form Strategic Collaboration to Develop Innovative Therapeutics for Oncology and Immunology

Harbour BioMed and PPD announced a strategic collaboration to develop HBM’s innovative therapeutics in the fields of oncology and immunology.

27 Aug. 2019

Evidera and CSS Collaborate to Develop Joint Real-world and Patient-centered Research Capabilities in Japan

Evidera, a business unit of PPD, has entered into an exclusive collaboration agreement with CSS, a subsidiary of SNBL, extending both organizations’ capabilities.

21 Aug. 2019

NeoGenomics Announces Grand Opening of new Pharma Services Laboratory in Singapore

NeoGenomics and PPD announced the grand opening of a NeoGenomics oncology-focused clinical trials testing lab in the same building as the PPD Laboratories central lab in Singapore.

31 Jul. 2019

Optimal Just-in-Time Service Changing the Paradigm of Cancer Trials

Optimal Just-in-Time, a service of PPD’s Accelerated Enrollment Solutions (AES) business unit, and Cancer Treatment Centers of America are collaborating to speed patient enrollment in oncology clinical trials.

16 Jul. 2019

Media Contacts:

Randy Buckwalter Senior Manager, Corporate Communications
Tel: +1 919 456 4425

Holly Devine Manager, Corporate Communications
Tel: +1 919 456 6389

Contact Legal Notices Modern Slavery Transparency Statement Privacy Policy

© 2019 Pharmaceutical Product Development, LLC. All rights reserved.